Overview

A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa

Status:
RECRUITING

Trial end date:
2032-10-31

Target enrollment:

Participant gender:

Summary

The Goal of this study is to evaluate the safety, tolerability, and clinical responses following single dose of DSP-3077. Study enrolls both male and female patients in 3 cohorts with each cohort defined by visual acuity (VA) criteria and dose level of DSP-3077. Each cohort will include 4 participants.

Phase:

PHASE1

Details

Lead Sponsor:

Sumitomo Pharma America, Inc.

Treatments:

KPNA1 protein, human